FindTrial
Sign In

To detect early changes of hydroxy chloroquine retinal toxicity by using Fundus auto fluorescence and spectral domain optical coherence tomography

Fundus auto fluorescence and spectral domain optical coherence tomography in early detection of hydroxy chloroquine retinal toxicity

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/07/044415
Enrollment
70
Registered
2022-07-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H36- Retinal disorders in diseases classified elsewhere

Interventions

None listed

Sponsors

sankara Eye Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are taking hydroxychloroquine for atleast 2 years for, RA, SLE, Sjogrenâ??s syndrome, Other connective tissue diseases

Exclusion criteria

Exclusion criteria: Anterior segment disease, Glaucoma, Nystagmus, Retinal disease especially macular pathology History of vitreoretinal surgery Media opacity preventing fundus view

Design outcomes

Primary

MeasureTime frame
To analyze Central Macular thickness and Fundus auto fluorescence changes in patients who is on hydroxychloroquine (HCQ) by spectral-domain optical coherence tomography (SD-OCT) and short-wavelength autofluorescence (SW-AF) Blue autofluorescence.Timepoint: Spectral-domain optical coherence tomography (SD-OCT) and short-wavelength autofluorescence (SW-AF) Blue autofluorescence on the day 1.—

Secondary

MeasureTime frame
To analyze the Visual outcome in patients who is on hydroxychloroquine (HCQ). Timepoint: Vision on the day 1—

Countries

India

Contacts

Public ContactDrMeera Nasrin

sankara eye hospital

drprabhushanker@gmail.com9443186568

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026